Skip to main content

About Enterra Medical

Our company’s mission

Enterra Medical is a medical device company dedicated to a singular focus: helping more people with chronic gastroparesis live better lives by advancing technology, expanding clinical science, and accelerating access to Enterra Therapy. 

In order to increase investment and focus on the therapy, Enterra Medical was formed in 2022 and has begun the process to assume ongoing responsibility of Enterra Therapy from Medtronic. This process began with commercial responsibilities and will continue to expand to other aspects of the business. Medtronic remains a strong operational partner in this new management model and will continue to handle customer and patient support until Enterra Medical is fully equipped to assume those functions. 

Gastroparesis is a condition in which food moves through the stomach too slowly, causing chronic nausea and vomiting. Enterra Therapy, approved by the FDA under a Humanitarian Device Exemption in 2000, is a surgical option for people unable to control chronic symptoms of gastroparesis.*  It is the first and only implantable therapy for Gastric Electrical Stimulation (GES) and over 15,000 people have received Enterra Therapy to help resume everyday activities.

MKT-D-0006, Rev E


Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.


Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?